Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers U > Headlines for UCB SA > News item |
UCB retained by Merrill Lynch at buy
UCB was retained by Merrill Lynch analyst Eric Whittaker at a buy rating with a price target on the stock of €48 per share following the company's positive phase III results for epilepsy drug Keppra as a monotherapy. On the Brussells exchange, UCB shares Thursday were down €0.18, or 0.40%, at €45.21 on volume of 201,088 shares versus the three-month running average of 330,611 shares.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.